Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells

Clinical trial NCT03554889 · UNKNOWN

Trial details

NCT number: NCT03554889
Sponsor: Hangzhou Cancer Hospital
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Cancer ADCC NK Cell Mediated Immunity Nimotuzumab Adaptive Transfer

Start date: 2018-08-01
Primary completion: 2019-03-30
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.